Peng Yang

age ~46

from Pittsburgh, PA

Get Report

Connected to:

Peng Yang Phones & Addresses

Pittsburgh, PA

Us Patents

Novel Cannabinoid Receptor 2 (Cb2) Inverse Agonists And Therapeutic Potential For Multiple Myeloma And Osteoporosis Bone Diseases
view source
US Patent:

20130172388, Jul 4, 2013
Filed:

Dec 14, 2012
Appl. No.:

13/715603
Inventors:

University of Pittsburgh -- Of the Commonwealth System of Higher Education - Pittsburgh PA, US
Rentian Feng - Pittsburgh PA, US
Peng Yang - Pittsburgh PA, US
Assignee:

University of Pittsburgh -- Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:

C07C 311/48
C07D 203/08
C07C 69/78
C07C 311/05
C07D 211/06
C07C 233/36
C07C 311/20
C07C 311/29
C07D 235/12
C07C 233/40
US Classification:

514331, 564157, 564155, 564158, 546231, 564 92, 564 89, 564123, 564192, 564182, 564 99, 5483094, 548966, 560107, 564 82, 514616, 514604, 514613, 514625, 514617, 514605
Abstract:

Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof:wherein: Rand Rare independently H, alkyl, or alkenyl; Ris alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; Rand Rare independently a bond, alkylenyl, or alkenylenyl; each Rand Ris independently selected from the group consisting of OH, F, Cl, Br, I, (C-C)alkyl, alkoxy, amino, COOH, CONH, SOH, POH, CN, SH, NOand CF; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.

Novel Cannabinoid Receptor Cb2 Ligand 4-(Aminomethyl)-N, N-Dialkylanilines
view source
US Patent:

20200270205, Aug 27, 2020
Filed:

May 11, 2020
Appl. No.:

16/872138
Inventors:

- Pittsburgh PA, US
Abdulrahman Almehizia - Pittsburgh PA, US
Peng Yang - Pittsburgh PA, US
Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA
International Classification:

C07C 311/29
C07D 405/12
C07D 409/12
C07D 333/34
C07D 333/38
C07C 311/13
C07C 311/18
C07D 401/12
C07D 241/44
A61P 19/10
A61P 35/00
C07D 213/42
C07D 317/58
Abstract:

Disclosed herein are novel cannabionid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).

Novel Cannabinoid Receptor Cb2 Ligand 4-(Aminomethyl)-N,N-Dialkylanilines
view source
US Patent:

20180141902, May 24, 2018
Filed:

Jun 17, 2016
Appl. No.:

15/580539
Inventors:

- Pittsburgh PA, US
Peng Yang - Pittsburgh PA, US
Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA
International Classification:

C07C 311/29
A61P 35/00
A61P 19/10
C07C 311/18
C07D 333/38
C07D 241/44
C07C 311/13
C07D 333/34
C07D 409/12
C07D 401/12
C07D 213/42
C07D 317/58
C07D 405/12
Abstract:

Disclosed herein are novel cannabinoid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).

Novel Cannabinoid Receptor 2 (Cb2) Inverse Agonists And Therapeutic Potential For Multiple Myeloma And Osteoporosis Bone Diseases
view source
US Patent:

20170001949, Jan 5, 2017
Filed:

May 31, 2016
Appl. No.:

15/169725
Inventors:

- Pittsburgh PA, US
Peng YANG - Pittsburgh PA, US
Rentian FENG - Pittsburgh PA, US
Assignee:

University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:

C07C 233/40
C07D 295/135
Abstract:

Cannabinoid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof:wherein: Rand Rare independently H, alkyl, or alkenyl; Ris alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; Rand Rare independently a bond, alkylenyl, or alkenylenyl; each Rand Ris independently selected from the group consisting of OH, F, Cl, Br, I, (C-C)alkyl, alkoxy, amino, COOH, CONH, SOH, POH, CN, SH, NOand CF; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.

Novel Cannabinoid Receptor 2 (Cb2) Inverse Agonists And Therapeutic Potential For Multiple Myeloma And Osteoporosis Bone Diseases
view source
US Patent:

20140296294, Oct 2, 2014
Filed:

Jun 16, 2014
Appl. No.:

14/305941
Inventors:

- Pittsburgh PA, US
Peng YANG - Pittsburgh PA, US
Rentian FENG - Pittsburgh PA, US
International Classification:

C07D 211/06
C07C 311/20
C07C 311/05
C07C 233/40
US Classification:

514331, 514616, 514604, 514613, 514625, 514617, 514605
Abstract:

Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof:

Resumes

Professor

view source

Location:

Pittsburgh, PA

Industry:

Pharmaceuticals

Work:

China Pharmaceutical University
Professor
Bioduro Aug 2017 - Feb 2018
Associate Director
University of Pittsburgh Dec 2015 - Jul 2017
Assistant Professor
University of Pittsburgh Jun 2011 - Nov 2015
Research Associate
Bioduro 2008 - 2011
Group Leader

Education:

Peking Union Medical College 2002 - 2008
Doctorates, Doctor of Philosophy, Philosophy, Organic Chemistry

Skills:

Medicinal Chemistry
Drug Discovery
Organic Synthesis
Drug Design
Organic Chemistry
Hplc
Chemistry
Pharmaceutical Industry
Lc Ms
Biochemistry
Nmr
Pharmacology
Lead Change
Mass Spectrometry
Uv/Vis
Drug Development
Parallel Synthesis
Biotechnology
Analytical Chemistry
Synthetic Organic Chemistry
Spectroscopy
Purification
Heterocyclic Chemistry
Chromatography
Ir
Chemdraw
Clinical Development
Lifesciences
Technology Transfer
Life Sciences
Bioinformatics
Cro
High Performance Liquid Chromatography

Languages:

English
Mandarin